Understand the source comparison
KPV for Rheumatoid Arthritis: Comparison with Conventional Treatments
NSAIDs (ibuprofen, naproxen) Inhibit COX-1/COX-2 enzymes, reducing prostaglandin synthesis Hours (symptom relief only) Gastric ulcers, cardiovascular risk, renal dysfunction KPV blocks upstream transcription rather than downstream enzyme activity—no GI or card
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- NSAIDs (ibuprofen, naproxen)
- Inhibit COX-1/COX-2 enzymes, reducing prostaglandin synthesis
- Hours (symptom relief only)
- Gastric ulcers, cardiovascular risk, renal dysfunction
- KPV blocks upstream transcription rather than downstream enzyme activity—no GI or cardiovascular toxicity
- DMARDs (methotrexate, sulfasalazine)
- Suppress T-cell and B-cell proliferation, reduce antibody production
- 8–12 weeks
- Hepatotoxicity, bone marrow suppression, immunosuppression
- KPV modulates inflammation without broad immunosuppression—doesn't increase infection risk
- Biologics (adalimumab, etanercept)
- Neutralize TNF-α after secretion
- 4–8 weeks
- Injection site reactions, reactivation of latent TB, increased infection risk
- KPV prevents TNF-α transcription before secretion—targets multiple cytokines simultaneously
- Corticosteroids (prednisone, methylprednisolone)
- Suppress NF-κB and AP-1 transcription factors broadly
- Hours to days
- Osteoporosis, hyperglycemia, adrenal suppression, cushingoid features
- KPV inhibits NF-κB selectively through melanocortin receptors without systemic glucocorticoid effects
- KPV (experimental)
- Prevents NF-κB nuclear translocation; stabilizes mast cells
- 2–4 weeks (anecdotal)
- Minimal reported—potential injection site irritation with subcutaneous dosing
- Modulates inflammation at transcriptional level; no immunosuppression or organ toxicity observed in preclinical models